This company is a clinical stage biotechnology business pioneering the discovery, development, and commercialisation of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
This company is a clinical stage biotechnology business pioneering the discovery, development, and commercialisation of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.